当前位置:首页>产品中心>单抗/多抗>Anti-Human APOBEC3C Polyclonal Antibody|抗人APOBEC3C多克隆抗体(靶标:人载脂蛋白B mRNA编辑酶催化多肽3C)

Anti-Human APOBEC3C Polyclonal Antibody|抗人APOBEC3C多克隆抗体(靶标:人载脂蛋白B mRNA编辑酶催化多肽3C)

  • 货号:RB9THA396014
  • 价格:面议
  • 点击:314

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标A3C, APOBEC1-like, APOBEC1L, APOBEC3C, DNA dC->dU-editing enzyme APOBEC-3C, EC:3.5.4.38, PBI, Phorbolin I
免疫原E. coli - derived recombinant Human APOBEC3C (Met12-Gln190).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q9NRW3
背景信息

DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) is a ~22 kDa protein. DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity against simian immunodeficiency virus (SIV), hepatitis B virus (HBV), herpes simplex virus 1 (HHV-1) and Epstein-Barr virus (EBV) and may inhibit the mobility of LTR and non-LTR retrotransposons.

备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 553
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 512
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 616
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 486
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 465
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 477
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 401
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 338
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 327
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 385
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 239
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 277
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 332
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 313
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 438
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 360
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 525
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 432
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 334
Anti-Sarilumab Non-Neutralizing Recombinant Antibody|抗萨瑞鲁单抗非中和重组抗体(靶标:萨瑞鲁单抗非中和抗体) 576
总计 33037 个记录,共 1652 页,当前第 1646 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00